Proteome Sciences PLC (GB:PRM)
LSE:PRM
Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)
Day’s Range― - ―
52-Week Range1.20 p - 4.40 p
Previous CloseN/A
Volume41.42K
Average Volume (3M)476.64K
Market Cap
£5.61M
Enterprise Value19.03M
Total Cash (Recent Filing)£781.00K
Total Debt (Recent Filing)£15.77M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Proteomics CapabilitiesA focused service offering in proteomics and mass spectrometry represents a technical specialization that is hard to replicate. This niche expertise supports long-term demand from pharma, biotech and academic customers for biomarker discovery and profiling, creating durable competitive positioning and opportunities for high-value project work.
Contract Research Fee-for-service ModelA fee-for-service model with one-off projects and longer-running service agreements aligns revenue to contracted lab work, promoting predictable cash inflows from repeat customers. When maintained, such client relationships create structural revenue stickiness and upsell potential tied to multi-year drug discovery programs.
Near-term Improvement In Cash Generation (2025)The 2025 move to near-breakeven operating cash flow and a much smaller free cash flow shortfall signals improving operational cash conversion. That improvement enhances short- to medium-term liquidity and suggests management actions may be beginning to stabilise funding needs, providing a more durable runway for executing strategy.
Bears Say
Revenue Decline And Loss-making OperationsA multi-year swing from prior profitability to sustained operating and net losses undermines margin sustainability and the firm's ability to scale. Declining top-line and negative gross profit indicate services are not absorbing fixed costs, pressuring long-term earnings potential and reducing the cushion against future demand shocks.
Stressed Balance Sheet And Rising LeverageHigh and rising debt combined with deeply negative equity materially constrain financial flexibility. Assets below debt and worsening equity elevate refinancing and covenant risk, increase the likelihood of dilution or costly financing, and limit the company's ability to invest in capacity or pursue strategic partnerships over the medium term.
Volatile And Historically Negative Cash FlowsA history of large swings and persistent negative free cash flow limits self-funding capacity and raises execution risk. Volatile cash generation reduces predictability for continued operations, increases dependence on external financing, and weakens the firm’s ability to sustain R&D or client-facing investments needed to win longer-term contracts.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £5.61M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Jul 23, 2026 which is in 48 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Apr 15, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---